Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Novo Nordisk Declares China's Supreme Court Supports Semaglutide Compound Patent - Featured image
Investing

Novo Nordisk Declares China's Supreme Court Supports Semaglutide Compound Patent

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·December 31, 2025·1 min read

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

This piece details the methodology behind super composite and composite ratings, incorporating key financial indicators. It stresses the need to examine associated descriptions closely. Investors should note coverage requirements for accurate calculations.

Share

Super Composite Rating Breakdown

The outstanding composite score stems from a weighted mean derived from rankings across these categories: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). It's crucial to examine the linked explanations thoroughly.

Composite Rating Methodology

The composite score arises from a mean of rankings based on these ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). For the computation to take place, the company requires coverage by at least 4 out of these 5 ratings. We urge you to review the correlated descriptions carefully.

Source Information

Originally published by Market Screener.Read the original article →

Read next

Keep exploring

More on semaglutide

Articles covering semaglutide dosing, side effects, and clinical updates.

Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
Endocrinology

Semaglutide and Tirzepatide: The Reality of Stopping and Restarting

A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.

7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
Men's Health

Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?

A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.

7 min read
Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior
Health & Wellness

Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior

Groundbreaking research indicates that GLP-1 receptor agonists, widely recognized for their impact on diabetes and weight management, may also play a crucial role in modulating impulsive behaviors that can lead to criminal acts and violence.

6 min read
Share this article
  1. Home
  2. Blog
  3. Novo Nordisk Declares China's Supreme Court Supports Semaglutide Compound Patent
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community